CTCE 0214

Drug Profile

CTCE 0214

Alternative Names: CTCE-0214

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chemokine Therapeutics
  • Class Chemokines
  • Mechanism of Action Chemokine CXCL12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Stem cell mobilisation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stem-cell-mobilisation in USA (SC)
  • 28 Dec 2006 Clinical data added to the adverse events and Haematological Disorders pharmacodynamics sections
  • 21 Jun 2006 Chemokine Therapeutics has entered into an agreement with Fred Hutchinson Cancer Research Center to investigate CTCE 0214 in repopulating blood stem cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top